Feasibility and Efficacy of A Yoga Intervention for Comorbid Chronic Pain and PTSD

November 7, 2023 updated by: Suzzette M. Chopin, PhD, Hunter Holmes Mcguire Veteran Affairs Medical Center

Yoga for Warriors: A Pilot Study of Feasibility and Efficacy of A Yoga Intervention for Veterans With Comorbid Chronic Pain and PTSD

The goal of this pilot quasi-randomized study is test the feasibility, acceptability, and initial efficacy of Yoga for Warriors treatment program for comorbid chronic pain and PTSD, conducted virtually through the Richmond Veterans Affairs Medical Center (RICVAMC).

the main questions it aims to answer are:

  1. Whether a virtual intervention for chronic pain and PTSD is feasible and acceptable for veterans.
  2. Using a wait-list control group design, to determine preliminary efficacy of the intervention.
  3. Examine follow-up data to determine if benefits are maintained over time.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study will be a pilot quasi-randomized controlled design comparing the 8-session Yoga for Warriors program, conducted via a web-based platform, utilizing a wait-list control, with wait-list participants being enrolled in subsequent groups. Measures of treatment satisfaction will be given and rates of initiation following screening and drop-out will be measured. A battery of assessments will be given at baseline (group introduction), at mid-point (around session 4), and following completion of the group. To determine maintenance effects, select assessments and re-administration of the study assessment battery will be conducted 3 months post-completion.

Potentially interested participants will be screened for eligibility. Screening for eligibility will occur over the phone and those who are interested in participating and willing to engage in the online format and who meet inclusion criteria based on study staff screening will go through the informed consent process over the phone or virtually. Collection of informed consent from participants will not include written documentation of informed consent given the fully virtual nature of this study during the coronavirus pandemic (COVID-19) restrictions (waiver of documentation of consent has been submitted). Paperless recording of willingness to participate will take place, with no written documentation of consent to participate. Participants will attend an initial online orientation session (prior to the first yoga session), either in a group format or individually, where they will be provided information on the group, will be randomized into the treatment group or to the wait-list control group. To attend the orientation session and all yoga sessions, participants will be emailed the specific, secured link to the online platform. Participants will complete the measures over the phone with the study coordinator. This will be an 8 week (+1 orientation session) group conducted remotely, online, with additional self-report measures completed mid-treatment, post-treatment, and at follow-up, in the same manner as described above.

Study Type

Interventional

Enrollment (Actual)

17

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Virginia
      • Richmond, Virginia, United States, 23249
        • Richmond Veterans Affairs Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of chronic pain (defined as pain for > 3 months) in the electronic medical record and a score of 50 or more on the Pain Disability Questionnaire (PDQ)
  • Probable PTSD defined as being above the clinical threshold on the PTSD Checklist for DSM-5 (PCL-5), sum score at or above 25
  • Able to stand up from sitting on the floor without assistance
  • Able to ambulate community distances without an assistive device
  • Intact sensation in lower extremities below knees
  • Medical clearance by primary care provider
  • Access to a computer/laptop/ipad with internet and video capability.

Exclusion Criteria:

  • Fall risk
  • Pregnancy
  • Joint replacement within the past 12 months
  • Active alcohol/other substance abuse or dependence (unless actively engaged in treatment)
  • Current psychotic disorder or hospitalization with psychotic symptoms in past 3 months
  • Active (past 3 months) suicidal or homicidal ideation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active
Immediately enrolled into Yoga intervention. Completed orientation and baseline measures then began 8-week yoga group intervention.
8 week Yoga for chronic pain and PTSD group intervention, conducted virtually
Other Names:
  • Complementary and Alternative Intervention
Other: Waitlist
Delayed Intervention. Waitlist individuals attended orientation and completed baseline measures. After completion of re-assessment of measures 8 weeks later, then enrolled into Active arm.
8 week Yoga for chronic pain and PTSD group intervention, conducted virtually
Other Names:
  • Complementary and Alternative Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PTSD Checklist for Diagnostic and Statistic Manual for Mental Disorders 5 (DSM-5)
Time Frame: past week; assessed at baseline, mid-treatment (after week 4), post-treatment (after week 8), 3 month follow up
Assess current symptoms of PTSD in line with DSM-5 criteria (20 items)
past week; assessed at baseline, mid-treatment (after week 4), post-treatment (after week 8), 3 month follow up
Pain Disability Questionnaire
Time Frame: past week; assessed at baseline, mid-treatment (after week 4), post-treatment (after week 8), 3 month follow up; Items rated on 1 to 10-point scale; higher scores indicate worse outcome
Assesses self report of impact of pain in functioning (15 items)
past week; assessed at baseline, mid-treatment (after week 4), post-treatment (after week 8), 3 month follow up; Items rated on 1 to 10-point scale; higher scores indicate worse outcome
Pain Catastrophizing Scale
Time Frame: current; past week; assessed at baseline, mid-treatment (after week 4), post-treatment (after week 8), 3 month follow up; Items rated 0 to 4; higher scores indicate worse outcomes
Assesses self report of thoughts and worries related to chronic pain (13 items)
current; past week; assessed at baseline, mid-treatment (after week 4), post-treatment (after week 8), 3 month follow up; Items rated 0 to 4; higher scores indicate worse outcomes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Client Satisfaction Questionnaire-8 (CSQ-8)
Time Frame: Time in intervention; Assessed at post-treatment (8 weeks); Items rated 1 to 4; higher scores indicate better outcomes
Th CSQ is an 8-item measure assesses general intervention satisfaction
Time in intervention; Assessed at post-treatment (8 weeks); Items rated 1 to 4; higher scores indicate better outcomes
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Past 2 weeks; assessed at baseline and post-treatment (8 weeks); Items rated 0 to 3; higher scores indicate worse outcomes
The PHQ-9 assesses depression severity
Past 2 weeks; assessed at baseline and post-treatment (8 weeks); Items rated 0 to 3; higher scores indicate worse outcomes
Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Time Frame: Past 2 weeks; assessed at baseline and post-treatment (8 weeks); Items rated 0 to 3; higher scores indicate worse outcomes
The GAD-7 measures anxiety experienced
Past 2 weeks; assessed at baseline and post-treatment (8 weeks); Items rated 0 to 3; higher scores indicate worse outcomes
Patient Reported Outcome Measurement Information System (PROMIS) Short Form Anger
Time Frame: Past 7 days; assessed at baseline and post-treatment (8 weeks); Items rated 1 to 5; raw scores converted to T scores; higher scores mean worse outcomes
Assesses emotional distress and anger (5 items)
Past 7 days; assessed at baseline and post-treatment (8 weeks); Items rated 1 to 5; raw scores converted to T scores; higher scores mean worse outcomes
Patient Reported Outcome Measurement Information System (PROMIS) Short Form Social Roles
Time Frame: Past 7 days; assessed at baseline and post-treatment; (8 weeks); Items rated 1 to 5; raw scores converted to T scores; higher scores mean better outcomes
Assesses ability to participate in social roles and activities
Past 7 days; assessed at baseline and post-treatment; (8 weeks); Items rated 1 to 5; raw scores converted to T scores; higher scores mean better outcomes
Tampa Scale for Kinesiophobia (TSK-11)
Time Frame: Current; assessed at baseline, mid-treatment (4 weeks), post-treatment (8 weeks), 3 month follow up; Items rated 1 to 4; higher scores indicate worse outcomes
The TSK-11 is an 11-item scale used to measure general perceptions of pain interference
Current; assessed at baseline, mid-treatment (4 weeks), post-treatment (8 weeks), 3 month follow up; Items rated 1 to 4; higher scores indicate worse outcomes
Quality of Life Enjoyment and Satisfaction Questionnaire -- Short Form (LES-Q-SF)
Time Frame: past week; assessed at baseline, post-treatment (8 weeks), 3 month follow up; Items rated 1 to 5; higher scores indicate better outcomes
The Q-LES-Q-SF is a 16-item scale used to measure quality of life
past week; assessed at baseline, post-treatment (8 weeks), 3 month follow up; Items rated 1 to 5; higher scores indicate better outcomes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Suzzette Chopin, Ph.D., Richmond Veteran Affairs Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2021

Primary Completion (Actual)

August 30, 2022

Study Completion (Actual)

August 30, 2022

Study Registration Dates

First Submitted

October 30, 2023

First Submitted That Met QC Criteria

November 7, 2023

First Posted (Estimated)

November 8, 2023

Study Record Updates

Last Update Posted (Estimated)

November 8, 2023

Last Update Submitted That Met QC Criteria

November 7, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1572859

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Fully de-identified participant level data and aggregate data (all collected IPD) will be made available to qualified researchers who contact the Study PI per the Institutional Review Board's approved data management and sharing plan.

IPD Sharing Time Frame

Starting 6 months following publication of primary dataset. Data will remain available for up to 10 years.

IPD Sharing Access Criteria

Qualified researchers (i.e., based on degree and institutional support) who request de-identified data from study PI (listed as corresponding author) following publication of primary paper. Relevant data dictionaries and analytic scripts may also be shared through encrypted email or file-sharing programs. PI/corresponding author will review requests and make final approval decisions for data sharing.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on PTSD

Clinical Trials on Yoga

Subscribe